Publications by authors named "Verze Michela"

Claim this Profile
Fusion as Resistance Mechanism to Osimertinib in -Mutated NSCLC: A Case Report and Review of Literature.
Marianna Peroni, Alessandro Leonetti, Roberta Minari, Michela Verzè, Letizia Gnetti

JTO Clin Res Rep· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumor DNA monitoring in advanced mutated melanoma (LIQUID-MEL).
Martines Gianmarco, Palazzi Carolina, Monica Gregorio, Verzè Michela, Pluchino Monica

J Liq Biopsy· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC.
Alessandro Leonetti, Veronica Cervati, Roberta Minari, Maura Scarlattei, Michela Verzè

Clin Lung Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors.
Giulia Mazzaschi, Fabiana Perrone, Giuseppe Maglietta, Elda Favari, Michela Verzè

J Immunother· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MET alterations as resistance mechanisms of dabrafenib-trametinib in BRAF p.V600E mutated non-small cell lung cancer patient.
Monica Pluchino, Irene Testi, Roberta Minari, Alessandra Dodi, Giulia Airò, Michela Verzè

Anticancer Drugs· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers.
Michela Verzè, Andrea Boscolo Bragadin, Roberta Minari, Giulia Pasello, Fabiana Perrone

J Liq Biopsy· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models.
Silvia La Monica, Federica Vacondio, Kamal Eltayeb, Alessio Lodola, Francesco Volta, Michela Verzè

Sci Rep· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors.
Fabiana Perrone, Elda Favari, Giuseppe Maglietta, Michela Verzè, Monica Pluchino

Cancer Immunol Immunother· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review.
Michela Verzè, Monica Pluchino, Alessandro Leonetti, Matilde Corianò, Francesco Bonatti

Transl Lung Cancer Res· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study.
Giulia Mazzaschi, Fabiana Perrone, Roberta Minari, Michela Verzè, Cinzia Azzoni

Clin Lung Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer.
Ingrid Garajová, Andrea Cavazzoni, Michela Verze, Roberta Minari, Giuseppe Pedrazzi

Life (Basel)· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups.
Fabiana Perrone, Giulia Mazzaschi, Roberta Minari, Michela Verzè, Cinzia Azzoni

Cancers (Basel)· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature.
Michela Verzè, Roberta Minari, Letizia Gnetti, Paola Bordi, Alessandro Leonetti

Cancers (Basel)· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial.
Alessandro Leonetti, Roberta Minari, Luca Boni, Letizia Gnetti, Michela Verzè

Clin Lung Cancer· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic Evaluation of Circulating miRNA Profile in -Mutated NSCLC Patients Treated with EGFR-TKIs.
Alessandro Leonetti, Mjriam Capula, Roberta Minari, Giulia Mazzaschi, Alessandro Gregori, Michela Verzè

Cells· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review.
Alessandro Leonetti, Roberta Minari, Giulia Mazzaschi, Letizia Gnetti, Silvia La Monica, Michela Verzè

Front Oncol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients.
Umberto Malapelle, Francesco Passiglia, Chiara Cremolini, Maria Lucia Reale, Francesco Pepe, Michela Verzè

Eur J Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis